OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Subscription and Copyright Information	850
Shearing of surface mucin saps tumor cell strength	541
Subscription and Copyright Information	395
Structural asymmetry in FGF23 signaling	219
Advisory Board and Contents	214
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	195
Subscription and Copyright Information	182
Subscription and Copyright Information	164
Muscarinic receptors: from clinic to bench to clinic	153
Subscription and Copyright Information	150
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	146
Peptides as a therapeutic strategy against Klebsiella pneumoniae	139
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	121
Swinging the SWI/SNF complexes for cancer therapy	121
Compstatins: the dawn of clinical C3-targeted complement inhibition	121
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	116
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	111
Targeting complement in neurodegeneration: challenges, risks, and strategies	106
Therapeutic inhibition of ferroptosis in neurodegenerative disease	105
Structural pharmacology and mechanisms of GLP-1R signaling	105
Direct in vivo CAR T cell engineering	94
Advisory Board and Contents	86
Nemolizumab (Nemluvio®) for prurigo nodularis	86
Ribosome-directed cancer therapies: the tip of the iceberg?	85
Phenotypic approaches for CNS drugs	84

A deep dive into degrader-induced protein-protein interfaces	80
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	79
Advisory Board and Contents	78
A perspective on psychedelic teratogenicity: the utility of zebrafish models	77
Advisory Board and Contents	76
Optogenetic engineering for precision cancer immunotherapy	70
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	69
A smart hospital-driven approach to precision pharmacovigilance	69
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	68
Leveraging human microbiomes for disease prediction and treatment	68
siRNA drug Leqvio (inclisiran) to lower cholesterol	67
HSV-1 as a gene delivery platform for cancer gene therapy	66
Emerging strategies for beta cell transplantation to treat diabetes	64
Engineering ACE2 decoy receptors to combat viral escapability	64
Close to a year in TIPS’ saddle – I am optimistic	64
Genetically engineered loaded extracellular vesicles for drug delivery	64
Subscription and Copyright Information	61
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Thriving as members of under-represented groups in pharmacology-related careers	56
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	55
Bimetallic nanoadjuvants for cancer vaccines	54
Advisory Board and Contents	54
Subscription and Copyright Information	53
Lipoxygenases in chronic liver diseases: current insights and future perspectives	53
Suzetrigine for moderate to severe acute pain	52
Could dexmedetomidine be repurposed as a glymphatic enhancer?	51